ALNYLAM PHARMACEUTICALS, INC. Accumulated Other Comprehensive Income
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Accumulated Other Comprehensive Income of -$32.14 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-07-30
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$32.14M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$20.10M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$21.77M.
- 2025-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$29.95M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$32.14M 10-Q · filed 2026-07-30 |
| 2025-12-31 | -$20.10M 10-Q · filed 2026-07-30 |
| 2025-09-30 | -$21.77M 10-Q · filed 2025-10-30 |
| 2025-06-30 | -$29.95M 10-Q · filed 2025-07-31 |
| 2025-03-31 | -$37.52M 10-Q · filed 2025-05-01 |
| 2024-12-31 | -$34.52M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$24.83M 10-Q · filed 2024-10-31 |
| 2024-06-30 | -$34.64M 10-Q · filed 2024-08-01 |
| 2024-03-31 | -$26.99M 10-Q · filed 2024-05-02 |
| 2023-12-31 | -$23.38M 10-K · filed 2025-02-13 |
| 2023-09-30 | -$32.34M 10-Q · filed 2023-11-02 |
| 2023-06-30 | -$37.08M 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$39.12M 10-Q · filed 2023-05-04 |
| 2022-12-31 | -$44.65M 10-K · filed 2024-02-15 |
| 2022-09-30 | -$43.78M 10-Q · filed 2022-10-27 |
| 2022-06-30 | -$42.22M 10-Q · filed 2022-07-28 |
| 2022-03-31 | -$38.06M 10-Q · filed 2022-04-28 |
| 2021-12-31 | -$33.26M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$34.23M 10-Q · filed 2021-10-28 |
| 2021-06-30 | -$36.08M 10-Q · filed 2021-08-03 |
| 2021-03-31 | -$36.72M 10-Q · filed 2021-04-29 |
| 2020-12-31 | -$43.62M 10-K · filed 2022-02-10 |
| 2020-09-30 | -$37.19M 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$33.21M 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$32.06M 10-Q · filed 2020-05-06 |
| 2019-12-31 | -$36.52M 10-K · filed 2021-02-11 |
| 2019-09-30 | -$34.37M 10-Q · filed 2019-10-31 |
| 2019-06-30 | -$35.83M 10-Q · filed 2019-08-06 |
| 2019-03-31 | -$32.85M 10-Q · filed 2019-05-02 |
| 2018-12-31 | -$33.21M 10-K · filed 2020-02-13 |
| 2018-09-30 | -$33.39M 10-Q · filed 2018-11-07 |
| 2018-06-30 | -$33.81M 10-Q · filed 2018-08-02 |
| 2018-03-31 | -$34.85M 10-Q · filed 2018-05-04 |
| 2017-12-31 | -$34.43M 10-K · filed 2019-02-14 |
| 2017-09-30 | -$33.74M 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$33.96M 10-Q · filed 2017-08-09 |
| 2017-03-31 | -$33.83M 10-Q · filed 2017-05-05 |
| 2016-12-31 | -$33.44M 10-K · filed 2018-02-15 |
| 2016-09-30 | -$27.78M 10-Q · filed 2016-11-03 |
| 2016-06-30 | -$28.30M 10-Q · filed 2016-08-04 |
| 2016-03-31 | -$9.01M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $4.37M 10-K · filed 2017-02-15 |
| 2015-09-30 | -$7.22M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $18.76M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $52.38M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $48.76M 10-K · filed 2016-02-12 |
| 2014-09-30 | $15.19M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $21.98M 10-Q · filed 2014-08-08 |
| 2014-03-31 | $25.03M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $19.72M 10-K · filed 2015-02-13 |
| 2013-09-30 | $27.17M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $28.13M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $20.82M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $15.66M 10-K · filed 2014-02-20 |
| 2012-09-30 | $108.00K 10-Q · filed 2012-11-05 |
| 2012-06-30 | -$62.00K 10-Q · filed 2012-08-08 |
| 2012-03-31 | -$37.00K 10-Q · filed 2012-05-03 |
| 2011-12-31 | -$165.00K 10-K · filed 2013-02-19 |
| 2011-09-30 | -$151.00K 10-Q · filed 2011-11-03 |
| 2011-06-30 | -$246.00K 10-Q · filed 2011-08-03 |
| 2011-03-31 | -$18.00K 10-Q · filed 2011-05-05 |
| 2010-12-31 | $714.00K 10-K · filed 2012-02-13 |
| 2010-09-30 | $1.29M 10-Q · filed 2010-11-04 |
| 2010-06-30 | $1.29M 10-Q · filed 2010-08-05 |
| 2009-12-31 | $716.00K 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |